Bio-Techne (Bio-Techne) Change In Receivables

: $-12 Mil (TTM As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

Bio-Techne's change in receivables for the quarter that ended in Dec. 2023 was $5 Mil. It means Bio-Techne's Accounts Receivable declined by $5 Mil from Sep. 2023 to Dec. 2023 .

Bio-Techne's change in receivables for the fiscal year that ended in Jun. 2023 was $-21 Mil. It means Bio-Techne's Accounts Receivable increased by $21 Mil from Jun. 2022 to Jun. 2023 .

Bio-Techne's Accounts Receivable for the quarter that ended in Dec. 2023 was $207 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Bio-Techne's Days Sales Outstanding for the three months ended in Dec. 2023 was 69.44.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Bio-Techne's liquidation value for the three months ended in Dec. 2023 was $-386 Mil.

Bio-Techne Change In Receivables Historical Data

The historical data trend for Bio-Techne's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

-15.00

6.56

-15.55

-57.60

-20.87

Bio-Techne Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-5.91	-32.20	-0.09	15.60	4.73

Bio-Techne Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12 Mil.

Bio-Techne (NAS:TECH) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Bio-Techne's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	207.451	/	272.598	*	91
=	69.44

2. In Ben Graham's calculation of liquidation value, Bio-Techne's accounts receivable are only considered to be worth 75% of book value:

Bio-Techne's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	135.652	-	767.194	+	0.75 * 207.451	+	0.5 * 180.839
=	-386

Bio-Techne Change In Receivables Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (Bio-Techne) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

TE1:Germany T1CH34:Brazil

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Executives

Roeland Nusse	director	473 TENNESSEE, PALO ALTO CA 94306
William Geist	officer: PRESIDENT, PROTEIN SCIENCES	900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth	director, officer: Chief Executive Officer	425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Robert V Baumgartner	director	5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
Kim Kelderman	officer: Pres. Diagnostics & Genom	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor	officer: SVP Biotech	8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel	officer: Chief Financial Officer	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan	director	C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Julie L Bushman	director	185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Randolph C Steer	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413